Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients with Chest Wall Breast Cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1)

被引：1
|
作者：
Valenza, Carmine
Giachetti, Pier Paolo Maria Berton
Zagami, Paola
Nicolo, Eleonora
Trapani, Dario
Boldrini, Laura
Salimbeni, Beatrice Taurelli
Ascione, Liliana
Antonarelli, Gabriele
Corti, Chiara
Esposito, Angela
Criscitiello, Carmen
Fusco, Nicola
Curigliano, Giuseppe
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-14-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-05
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Correlation Between Programmed Death-1 (PD-1) Expression in Tumor Infiltrating Lymphocytes and Programmed Death Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Carcinoma
    Driver, Brandon
    Miller, Ross A.
    Deavers, Michael
    Tacha, David
    Bernicker, Eric
    Cagle, Philip T.
    LABORATORY INVESTIGATION, 2017, 97 : 475A - 475A
  • [32] PD-L1 (Programmed Death-Ligand 1) Expression is Associated with Increased CD8+Tumour-Infiltrating Lymphocytes (TILs) in Oropharyngeal Squamous Cell Carcinoma (OPSCC)
    Woods, G. B.
    O'Farrell, N.
    Kennedy, S.
    O'Neill, J. P.
    Leader, M.
    JOURNAL OF PATHOLOGY, 2018, 246 : S42 - S42
  • [33] Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients
    El-Guindy, Dina M.
    Helal, Duaa S.
    Sabry, Nesreen M.
    El-Nasr, Mohamed Abo
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (04) : 125 - 131
  • [34] Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis
    Zou, Ming-Xiang
    Peng, An-Bo
    Lv, Guo-Hua
    Wang, Xiao-Bin
    Li, Jing
    She, Xiao-Ling
    Jiang, Yi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (07): : 3274 - 3287
  • [35] Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
    Li, Huijuan
    Lin, Dang
    Lv, Tangfeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022,
  • [36] Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions
    Yagyuu, Takahiro
    Hatakeyama, Kinta
    Imada, Mitsuhiko
    Kurihara, Miyako
    Matsusue, Yumiko
    Yamamoto, Kazuhiko
    Obayashi, Chiho
    Kirita, Tadaaki
    ORAL ONCOLOGY, 2017, 68 : 36 - 43
  • [37] Crosstalk between programmed death ligand 1 (PD-L1) expression, Ki-67 labelling index and tumour infiltrating lymphocytes (TILs) in invasive breast cancer: a tertiary care centre study
    Sharma, R.
    Elhence, P.
    Rao, M.
    Khera, S.
    Chaudhary, R.
    Pareek, P.
    Vishnoi, J. R.
    VIRCHOWS ARCHIV, 2020, 477 : S53 - S54
  • [38] The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
    Ness, Nora
    Andersen, Sigve
    Khanehkenari, Mehrdad Rakaee
    Nordbakken, Cecilie V.
    Valkov, Andrej
    Paulsen, Erna-Elise
    Nordby, Yngve
    Bremnes, Roy M.
    Donnem, Tom
    Busund, Lill-Tove
    Richardsen, Elin
    ONCOTARGET, 2017, 8 (16) : 26789 - 26801
  • [39] Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with stage IIIb colorectal cancer.
    Koganemaru, Shigehiro
    Inoshita, Naoko
    Miura, Yuji
    Fukui, Yudai
    Ozaki, Yukinori
    Tomizawa, Kenji
    Hanaoka, Yutaka
    Toda, Shigeo
    Suyama, Koichi
    Tanabe, Yuko
    Moriyama, Jin
    Fujii, Takeshi
    Matoba, Shuichiro
    Kuroyanagi, Hiroya
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [40] Tumor-infiltrating lymphocytes (TILs) status, programmed death-ligand 1 (PD-L1) expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses
    Xiao, Xuexue
    Jin, Su
    Zhangyang, Geling
    Xiao, Shiwei
    Na, Fang
    Yue, Junqiu
    GLAND SURGERY, 2022, 11 (06) : 1037 - 1046
12345